Australia's largest stock trading and investment forum Australia's #1 stock forum

CAI

Click for more information

0.00%

11.5¢ calidus resources limited

Ann: Calidus Investor Webinar, page-8

First 8 Last

Share
Profile

Follow
DANNY2503

1,494 Posts.

722

31/10/23

14:38

Post #: 70642690
Share

Originally posted by Load: ↑

I only caught the tail end of this webinar. Can someone give us a summary if they attended?

I saw Dave wouldnt be drawn on the grade of WGP for H2 FY24, but claimed it would be substantially more than what we have been getting as they work down closer to the richer stuff..
Nothing in his demeanour suggested Pirra was going to be divested, nor the the company is in dire financial straits. Still talking about 100K oz p.a. coming.

Im slightly skeptical and out until we see grade improvement from the additional ore in the satellite deposits. If Dave can swing that and make it a success, I think CAI will re rate significantly and at a fast clip.

Bring on Q1 24 and Blue Bar! GLTAH.

Expand

The grade question he said he was unable to answer due to it not being released to market yet.

GLTAH
DYOR

CAI Price at posting: 18.5¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

EEG

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

CUF

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

HotCopper Highlights: Your most watched stocks for Week 46, 2024

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

First 8 Last

Add CAI (ASX) to my watchlist

SPONSORED BY